CCL2 and type 1 diabetes mellitus: Angiogenic ELISA assay (Fig. 5A) shows that APX3330 decreases plasminogen activator inhibitor type 1 (PAI-1, 5-fold, Fig. 5B), monocyte chemotactic protein-1 (MCP1, 3-fold, Fig. 5C) and MMP9 (3-fold, Fig. 5D) compared to T1DM-MCAo control rats.